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Abstract  96 
Growing data from epidemiological studies highlight the association between excess body fat 97 
and cancer incidence, but good indicative evidence demonstrates that intentional weight loss, 98 
as well as increasing physical activity, offers much promise as a cost-effective approach for 99 
reducing the cancer burden.  However, clear gaps remain in our understanding of how 100 
changes in body fat or levels of physical activity are mechanistically linked to cancer, and the 101 
magnitude of their impact on cancer risk. It is important to investigate the causal link between 102 
programmes that successfully achieve short-term modest weight loss followed by weight loss 103 
maintenance and cancer incidence. The longer-term impact of weight loss and duration of 104 
overweight and obesity on risk reduction also need to be fully considered in trial design. These 105 
gaps in knowledge need to be urgently addressed to expedite the development and 106 
implementation of future cancer control strategies. Comprehensive approaches to trial design, 107 
Mendelian randomisation studies and data linkage opportunities offer real possibilities to 108 
tackle current research gaps. In this paper, we set out the case for why non-pharmacological 109 
weight management trials are urgently needed to support cancer risk reduction and help 110 
control the growing global burden of cancer. 111 
112 







Cancer causes one in six deaths globally and is now overtaking cardiovascular disease as the 114 
leading cause of death across much of the world1,2. Currently, tobacco use is the most 115 
important single modifiable risk factor for cancer, but obesity (and its determinants — high 116 
intakes of energy-dense, ultra-processed foods and drinks, and low levels of physical activity) 117 
is becoming increasingly visible as the second most common cause of cancer. According to 118 
the World Health Organisation (WHO), 1.9 billion adults and over 340 million children and 119 
adolescents were living with overweight or obesity in 2016 (that is a Body Mass Index BMI 120 
greater than 25kg/m2) and these numbers are projected to rise3. This situation is compounded 121 
by global physical activity data suggesting that more than a quarter of the world’s population 122 
is insufficiently active4. Furthermore, overweight and obesity are occurring at earlier ages3, 123 
thereby increasing lifetime exposure to associated risks. Current estimates suggest that 124 
overweight and obesity could overtake smoking as the single biggest cause of cancer in UK 125 
women in around 25 years5 and this premise is also echoed in international reports6. Of all 126 
new global cancer cases in 2012, 481,000 (or 3·6%) were considered to be attributable to 127 
excess Body Mass Index (BMI)7  128 
The substantial reduction in lung cancer incidence in countries where public health initiatives 129 
have brought about a significant decrease in smoking indicates the potential of primary cancer 130 
prevention by societal interventions. The implementation of equitable, population-wide 131 
programmes for obesity prevention and management are eagerly awaited, but sufficient 132 
evidence already currently exists to justify a research focus on intentional weight loss and 133 
cancer risk reduction trials. The ultimate objective of trials with positive results must be to 134 
create further leverage for the development and implementation of policies aimed at improving 135 
the health of the general public — not just the individuals who have the resources and 136 
motivation to participate in individually-focussed weight loss programmes. 137 






Pharmaceutical options are available to reduce the risk of obesity-related diabetes and heart 138 
disease, but the portfolio of agents that reduce the risk of developing cancer is very limited. 139 
Considerable amounts of data, including evidence from randomised controlled trials, support 140 
the role of aspirin and tamoxifen in reducing colorectal cancer and breast cancer risk, 141 
respectively, and, although further studies also support a role for other drugs, such as 142 
metformin8,9 and statins10, in cancer prevention, the evidence is much weaker. The 143 
effectiveness of these pharmaceuticals is relatively modest compared with drugs available for 144 
treating cardiovascular risk factors (hypercholesterolemia, hypertension and insulin 145 
resistance/hyperglycaemia). In addition, the mechanisms of action of these potential cancer 146 
preventive agents are not well-established, and their pleiotropic and undesirable side-effects 147 
must be considered11 alongside evidence of inverse associations with mortality12 148 
 149 
Based on the disappointing results of a number of cancer chemoprevention trials conducted 150 
over the past three decades13, it is difficult to predict how long it will take to identify effective 151 
drugs with low risk of side-effects, and we cannot afford to wait for pharmacological 152 
approaches alone to prevent cancer risk.  The benefit to potentially affected individuals and 153 
their families and the direct and indirect economic implications of cancer risk reduction are far-154 
reaching. Addressing cancer prevention beyond pharmacological solutions has therefore 155 
become a global imperative, and strategies that offer disease reduction should no longer be 156 
ignored.  We now have the evidence to demonstrate that intentional weight loss and weight 157 
management as well as increasing physical activity offer much promise as cost-effective 158 
approaches for reducing the risk of developing cancer   159 
  160 
 Obesity and cancer   161 
The association between obesity and cancer has been reported and discussed in the literature 162 
since the early part of the 20th century14 As population rates of overweight and obesity continue 163 
to rise, so will the incidence of common cancers linked to excess body fat (EBF). As a 164 






consequence, escalating costs attributable to future cancer treatments and the long-term 165 
clinical management of associated comorbidities will place an unrelenting economic burden 166 
on healthcare systems. Action needs to be taken now, otherwise our failure to seriously 167 
address this topic will leave a sad legacy for the next generation  168 
 169 
Evidence of an association between excess body fatness and cancer.  170 
There is a strong need to address the role of EBF in early life, as it has been demonstrated to 171 
influence the risk of many diseases, including cancer, in adulthood. Hidayat et al.15 reported 172 
associations between body fatness at a young age and the development in later life of eight 173 
types of cancer. Jensen et al.16 subsequently reported from the Copenhagen School Health 174 
Records Registry that children who were heavier or gaining more weight than average at 7 to 175 
13 years of age  (n= 257,623) had a significantly greater risk of adult colon cancer.  176 
In adulthood, it seems that although the link between obesity and cancer is becoming more 177 
apparent, the significance of weight gain across adult life remains largely ignored. Not only is 178 
weight gain the pathway to overweight and obesity but it is also an independent risk factor for 179 
post-menopausal breast cancer risk (around 6% per 5kg increase in adult weight17), which is 180 
probably most relevant in women with a body mass index (BMI) <23.4 kg/m2 at age 20 (who 181 
are more likely to gain weight in adulthood than women with a BMI >23.4kg/m2).18 182 
The latest (2018) World Cancer Research Fund (WCRF)/American Institute for Cancer 183 
Research (AICR) expert report17 concluded that being overweight or obese throughout 184 
adulthood increases the risk of cancers of the mouth, pharynx, larynx, oesophagus 185 
(adenocarcinoma), stomach (cardia), pancreas, gall bladder, liver, colorectum, breast (post-186 
menopausal), ovary, endometrium, prostate (advanced) and kidney. In addition, a WHO 187 
International Agency for Research on Cancer (IARC) Working Group found evidence relating 188 
EBF to meningioma, thyroid cancer and multiple myeloma,19 and a hospital-based Danish 189 






study of 313,221 patients reported overweight and obesity being related to haematological 190 
and neurological cancers20. The reported inverse associations between physical activity and 191 
the risk of cancer at 13 sites, including some of the most common cancers (breast, lung, bowel 192 
and kidney)21,22 reflects the important role of a physically active lifestyle in cancer prevention, 193 
either via direct mechanisms, such as improved metabolic control or via its role in the 194 
prevention of adult weight gain23. Furthermore, studies show that structured exercise in 195 
combination with support for dietary-led weight loss induces more weight loss than exercise 196 
or diet alone and has the greatest impact on blood-borne biomarkers associated with common 197 
cancers, including insulin resistance and circulating levels of sex hormones, leptin and 198 
inflammatory markers24- 28.    199 
 200 
Mendelian randomisation studies.    201 
In the absence of randomised clinical trials, evidence for causality can be strengthened by 202 
Mendelian randomisation (MR) studies29. MR is an instrumental variables method to appraise 203 
causality within observational epidemiology, utilising germline genetic variants that are 204 
robustly associated with potentially modifiable exposures as proxies (‘instrumental variables’) 205 
for the risk factor of interest. As germline genetic variants tend to be randomly distributed with 206 
respect to most human traits in the general population, MR studies are less likely to be affected 207 
by the sorts of confounding factors that typically bias observational findings. Additionally, as 208 
germline genotypes cannot be affected by the presence of disease, the generation of spurious 209 
results through reverse causation is avoided. The objective is to identify modifiable 210 
intervention targets (behavioural or therapeutic) on the intermediate causal pathway between 211 
genetic factors and disease.  DNA, although itself unmodifiable, operates through modifiable 212 
pathways e.g. the proprotein convertase subtilisin/kexin type 1 (PCSK1) gene regulates 213 
insulin synthesis; fat mass- and obesity-associated (FTO) gene promotes food intake.    MR 214 






exploits this to identify modifiable exposures that can be used for disease prevention and 215 
therapeutic strategies.  216 
Studies using MR support the influence of higher body fatness on greater risk of oesophageal, 217 
gastric, pancreatic, renal, colorectal, endometrial and ovarian cancers30-33. Indeed, MR 218 
analysis suggests that the obesity-related cancer burden has been substantially 219 
underestimated34. The volume and location of fat tissue are strong determinants of insulin 220 
resistance and dyslipidaemia, and MR studies support strong effects of higher BMI on higher 221 
fasting levels of insulin, glucose, triglycerides, remnant cholesterol, and lower high-density 222 
lipoprotein (HDL) cholesterol35. The adverse metabolic effects of higher fatness are already 223 
evident in late childhood and might worsen with longer time exposure36. Higher body fatness 224 
also raises systolic and diastolic blood pressure, and impairs immunity via its association with 225 
elevated pro-inflammatory factors such as interleukin-637. Several of these metabolic traits are 226 
associated with an increased risk of obesity-related cancers, with MR evidence being 227 
strongest for higher fasting insulin38. 228 
  229 
Excess body fatness and breast cancer risk.  It is important to note that, from a life-course 230 
perspective, higher body fatness in childhood and adolescence is inversely related to the risk 231 
of pre-menopausal breast cancer as well as post-menopausal breast cancer39, suggesting a 232 
long-term protective effect of EBF on breast cancer risk later in life.  Analysis from the cohort-233 
pooling project papers40 on premenopausal breast cancer confirms that relative overweight at 234 
age 18–24 is associated with a modest reduction in the risk of pre-menopausal breast cancer 235 
up to the age of ~50 years, and additional analyses41 indicate that weight gain from ages 18–236 
24 to 35–44 or to 45–54 years is also inversely associated with breast cancer overall (e.g. 237 
hazard ratio [HR] per 5 kg to ages 45–54: 0.96, 95% confidence interval [CI]: 0.95–0.98) and 238 
with oestrogen-receptor(ER)-positive breast cancer (HR per 5 kg to ages 45–54: 0.96, 95% 239 
CI: 0.94–0.98).  240 






Evidence related to MR studies also indicates that a genetically predicted larger body size at 241 
age 10 might protect against breast cancer in women independent of subsequent body size 242 
at a mean age of 56.5 years42. These findings suggest that the effect of early-life body size 243 
might persist into later life regardless of interventions to influence adult body size. There is 244 
also evidence18 that early life body size exerts a protective effect even when accounting for 245 
age at menarche. A better understanding of the mechanisms linking childhood body size and 246 
timing of puberty with later breast cancer risk could help inform potential interventions. 247 
Understanding the crossover effect of obesity with risk reduction before, and risk increase 248 
after, menopause is poorly characterised and further work aimed at understanding the 249 
biological mechanisms of how obesity, weight gain and weight change all impact on breast 250 
cancer risk is needed17. However, the inverse association of obesity with pre-menopausal 251 
breast cancer does not alter the overall harmful effects of obesity given that weight and weight 252 
gain are positively associated with risks of postmenopausal breast cancer, several other types 253 
of cancer, and other adverse health outcomes. In addition, women with obesity or who have 254 
obesity diagnosed with breast cancer are more likely to have poorer outcomes than leaner 255 
women (independent of their menopausal status)43.  256 
 257 
Weight management — evidence of promise from observational studies 258 
Until 2010 the evidence that intentional weight loss in adulthood modifies cancer risk was 259 
sparse, and mostly relied on self-reported body weight with relatively short follow-up periods. 260 
However, long-term follow-up data from the Women’s Health Initiative cohort have since 261 
reported that, after a mean follow-up of 11.4 years, women with modest weight loss (≥ 10 262 
pounds from baseline weight during the initial three-year study) had a lower risk of endometrial 263 
cancer compared with those who did not lose weight44. This association was strongest among 264 
women with obesity or that had obesity at baseline. In this cohort, a lower risk of breast cancer 265 
among women who lost weight compared with women whose weight remained stable was 266 






also reported45. Similarly, the 17-year follow-up of the UK Women’s Cohort Study has shown 267 
a lower risk of post-menopausal breast cancer in those individuals who lost weight compared 268 
to women with stable weight or those who gained weight46.  269 
 270 
The largest study to date on weight change and post-menopausal breast cancer is from the 271 
Pooling Project of Prospective Studies of Diet and Cancer (DCPP),47 which assessed data 272 
from 180,885 women aged ≥ 50 years in whom 6930 invasive breast cancers were identified 273 
at final follow-up. All women were surveyed at three points (baseline, first follow-up (mean of 274 
5.2 years) and final follow-up (10 years)). Sustained weight loss was defined as no less than 275 
2 kg lost between baseline and first follow-up, which was not regained by final follow-up.  The 276 
results demonstrated that, compared with women with stable weight, women with sustained 277 
weight loss had a lower risk of breast cancer than women whose weight remained stable; 278 
moreover, the larger the weight loss, the lower the risk. It is notable that even modest weight 279 
loss (2–4.5 kg) was associated with a significant reduction in risk (HR 0.87, 95% CI 0.77–280 
0.99). Risk reduction was specific to women not using postmenopausal hormone replacement 281 
therapy and the lowest risk was for women who sustained at least 9 kg of weight loss (who 282 
were not taking hormone therapy).  283 
 284 
Weight management – indications from intervention studies   285 
Evidence for the impact of weight loss on cancer risk reduction is also emerging from 286 
intervention studies, although no study has yet been designed (in terms of size and follow-up 287 
period) specifically to assess the effects of weight loss on cancer incidence or mortality in the 288 
general population. Several studies have evaluated the effect of bariatric surgery on cancer 289 
risk, comparing people with obesity who underwent surgery with that of individuals in an 290 
obesity (non-randomised) control group who did not. According to a systematic review, 291 






bariatric surgery was reported to be associated with a reduction in the incidence of overall 292 
cancer (Pooled Odds Ratio (POR) = 0.72: 95% CI 0.59–0.87) and in the incidence of obesity-293 
related cancers (POR=0.55: 95% CI 0.31–0.96)48. The cancer-protective effect of bariatric 294 
surgery seems to be more pronounced in women than in men, and most marked for a 295 
reduction in breast cancer risk. It is notable that the favourable impact of bariatric surgery on 296 
cancer risk for adults in mid- and later-life occurs within a relatively short follow-up period and 297 
is independent of physical activity.  However, people undergoing bariatric surgery do not 298 
necessarily reflect the general overweight and obese population, and the physiological 299 
response following acute weight loss might in itself produce effects that might not be matched 300 
by weight loss induced through lifestyle interventions49. A systematic review of weight loss 301 
trials50 reported a significant reduction in the risk of all-cause mortality, cardiovascular mortality 302 
and cancer mortality. Furthermore, in 2020 the Look Ahead Research Group reported51 that 303 
an intensive lifestyle intervention trial of 5145 participants which targeted weight loss 304 
successfully  lowered incidence of obesity‐related cancers by 16% in adults with 305 
overweight or obesity and type 2 diabetes after a median follow of 11 years, 306 
highlighting the potential success of such interventions in cancer risk reduction 307 
 308 
Considerations in the design of trials investigating the influence of weight loss on 309 
cancer risk    310 
Irrespective of the mode of weight loss, it is important to investigate whether or not 311 
programmes that successfully achieve short-term modest weight loss followed by weight loss 312 
maintenance confer benefit on cancer incidence. The potential effect of latency of risk 313 
reduction following weight loss, as well as the duration of overweight and obesity, need to be 314 
fully considered in trial design. Furthermore, it is important to identify whether or not the 315 
benefits of weight loss are offset by any subsequent regain in weight. There is much to be 316 
learnt from highly successful diabetes prevention programmes based on change in caloric 317 






intake and increased physical activity for weight loss52,53  and it is particularly notable that in a 318 
15-year follow-up of the Diabetes Prevention Program, the incidence of diabetes still remained 319 
lower — by 27% — in the lifestyle intervention group compared with the placebo group54. 320 
 321 
The influence of physical activity    322 
Whilst reduced caloric intake plays a greater role than physical activity in weight loss55, the 323 
latter might be particularly important in weight loss maintenance56. However, it is likely that 324 
physical activity confers additional benefits on the reduction of cancer risk, for example 325 
through modulation of immune-regulatory pathways57 , reduced oxidative stress58, epigenetic 326 
changes59 and reduced telomere attrition60, that may be independent of its effects on body 327 
weight21. A 2020 MR study using data from the UK Biobank showed that physical activity is 328 
inversely associated with breast and colon cancer risk, independent of its effect on adiposity  329 
and the association between physical activity and cancer incidence at 10 sites was shown to 330 
be independent of BMI61.   Furthermore, strength training, which builds skeletal muscle mass, 331 
is inversely associated with the risk of bladder, kidney and colorectal cancer62,63. 332 
Improvements in insulin sensitivity and glucose homeostasis induced by aerobic exercise 333 
and/or strength training64 could reduce the risk of cancers associated with insulin resistance 334 
(and associated cellular signalling pathways), including cancers of the colon, liver, pancreas 335 
and endometrium65.  336 
 337 
The influence of dietary factors  338 
Similarly, it is important to consider the independent impact of dietary factors both in terms of 339 
macronutrient and micronutrient composition. Strong evidence exists for a protective role of 340 
several dietary factors in colorectal cancer (wholegrains, foods containing dietary fibre and 341 
dairy products) but less so for other cancer sites66. Whilst there has been some promising 342 






evidence for the beneficial role of fruit and vegetables in reducing cancer risk the overall 343 
impact on cancer burden is largely limited to cancers of the respiratory and upper digestive 344 
tract 66,67.  Furthermore, enthusiasm for micronutrient supplementation to reduce cancer risk 345 
has diminished following a number of randomised control trials that have produced evidence 346 
of an associated increased risk of cancer 68,69. The lack of impact of single nutrients/foods on 347 
cancer prevention does not mean that the quality of the diet can be ignored. Cancers arising 348 
from aberrant metabolic pathways are likely to be influenced by the same nutrients and foods 349 
that are associated with the risk of diabetes70 and there is some evidence that healthy dietary 350 
patterns (diets that are high in vegetables, fruit, whole grains, legumes and nuts) are 351 
beneficial. In turn, foods that promote weight gain (e.g. sugar-sweetened beverages), along 352 
with red and processed meats and alcohol, should be minimised — alcohol consumption is 353 
not only a contributor to caloric intake but also a recognised carcinogen17 354 
Weight management   355 
Focus on weight management enables a lifestyle pattern combining diet quality and quantity, 356 
alcohol intake and physical activity to be promoted and tested.  Given the tendency for lifestyle 357 
behaviours to cluster/co-occur71, implementation of equitable interventions that impact on 358 
several key areas of lifestyle offer considerable scope for reducing the overall disease burden. 359 
Although many unanswered questions exist within lifestyle interventions, with respect to dose, 360 
duration, type (for physical activity), caloric composition and diet quality (in terms of food 361 
intake), and how best to support long-term adherence, there is much that we can learn from 362 
longer-term lifestyle trials including those focusing on diabetes prevention. For example, 363 
intervention design no longer focuses on knowledge exchange alone but integrates goal -364 
based behavioural interventions, the use of lifestyle coaches, frequent contact and support 365 
and “toolbox strategies” to enable individual tailoring72. Furthermore, recent work has 366 
highlighted the impact of using behavioural change techniques to support changes in diet and 367 
physical activity 73. 368 






  369 
Weight loss trials — challenges and opportunities 370 
The potential for ‘megatrials’ to answer nutritional questions has been described by 371 
Trepanowski and Ioannidis74 to address challenges such as selective reporting, small  sample 372 
size, short length of follow-up and high costs (trials of non-pharmacological interventions are 373 
generally publicly funded, with relatively low budgets, which makes large sample sizes and 374 
lengthy follow-up protocols prohibitive). These challenges are common in nutritional trials (as 375 
with other clinical areas) and it is clear that the methodological rigour of complex dietary 376 
behavioural trials needs to improve. In reality, large randomised controlled trials are likely to 377 
improve our understanding of the impact of weight management on cancer risk but will need 378 
to be considered alongside other data sources such as pooled cohort studies75, triangulated 379 
MR approaches (see Figure 1)76 and network meta-analysis77. The science of trial design78 380 
now offers a much clearer pathway for designing and addressing trial challenges, enabling 381 
researchers to optimise recruitment from populations of interest, incorporate intervention 382 
features (content, implementation, fidelity and adherence), comparator groups, adaptive trial 383 
design79, and to collect long-term outcomes. The key here is to assess the body of evidence 384 
appropriately by recognising the inherent weaknesses in the various research designs that 385 
contribute to it.  386 
 387 
Although three decades of trials of behavioural weight loss programmes such as the Diabetes 388 
Prevention Program have successfully demonstrated a significant reduction in the incidence 389 
of diabetes, weight loss programmes for cancer prevention have not received much funding.   390 
A 21st century rationale (as described by Ballard et al80) for this lack of investment points to a 391 
lack of good interim biomarkers, the need for prohibitively large sample sizes, uncertainties 392 
about life stage and appropriate ‘dose’ of intervention, the need to achieve sustained 393 
behaviour change and the apparent desire for genetic discoveries. There are also concerns 394 






that people who attempt and fail to adhere to weight loss regimens might experience negative 395 
emotional responses and, indeed, self-blame if a subsequent diagnosis of cancer is made. 396 
However, the past decade has seen a portfolio of weight loss regimens combining novel 397 
dietary approaches, motivational technologies and implementation science approaches, which 398 
will help to optimise adherence and provide supportive behaviour change strategies for weight 399 
loss trials81,82. Although multi-component interventions offer significant challenges, such 400 
approaches have been successfully tested in diabetes83 and cognitive function84 contexts, and 401 
are feasible to implement. Modern wearable technologies to motivate and support behaviour 402 
change, remote objective data collection and record linkage to routine clinical or registry data 403 
for follow-up (of at least a decade) make some of the difficulties in cancer prevention trials 404 
more manageable. Furthermore, improvements in trial design, understanding of intervention 405 
content and dose, and knowledge regarding the provision of effective long-term support for 406 
behaviour change make successful cancer prevention trials increasingly plausible. 407 
Nevertheless, an important challenge for primary prevention trial design is the identification of 408 
clinically meaningful short- and longer-term health outcomes. The search for robust and 409 
clinically relevant surrogate markers (e.g. adenoma recurrence in colorectal cancer, 410 
mammographic density, hormone levels in breast cancer etc.) continues, and such markers 411 
would add considerable confidence to expensive intervention studies with long-term follow-412 
up. However, it is also important to note that studies of chemoprevention (e.g. aspirin) that 413 
have cancer development as their primary outcome have been funded, and lifestyle 414 
interventions could do likewise. 415 
 416 
Weight management and high-risk populations.   417 
One notable population of interest for weight management trials includes people who are 418 
known to be at a higher risk of developing cancer, including those with a family history of 419 
colorectal or breast cancer who are already undergoing surveillance procedures. In a large 420 
international multicentre trial of aspirin in patients with Lynch syndrome (hereditary non-421 






polyposis colorectal cancer), Movahedi et al.85 reported that participants with obesity were 422 
2.41 times (95% CI, 1.22 to 4.85) more likely to develop colorectal cancer than participants 423 
with under- and normal-weight, and their risk increased by 7% for each 1 kg/m2 increase in 424 
BMI. There is considerable interest in weight management in women with a family history of 425 
breast cancer, although the greatest efforts to date have focussed on physical activity 426 
interventions. Gramling et al.86 reported from the Women’s Health Initiative observational study 427 
that healthy lifestyles (i.e regular exercise, healthy body weight on the basis of BMI and <7 428 
alcoholic drinks per week) led to a reduction in the risk of breast cancer in postmenopausal 429 
women, and the degree of this benefit was similar for women with and without a family history 430 
of breast cancer. A review by  Pettapiece-Phillips et al.87 reported evidence of a protective role 431 
of a healthy body size and regular physical activity among BRCA mutation carriers, notably in 432 
adolescence and early adulthood. A number of feasibility or pilot trials of weight management 433 
have been undertaken in this high-risk population, including an assessment of the Diabetes 434 
Prevention Program (with modifications) on breast cancer risk biomarkers88. Intervention 435 
studies involving diet and physical activity89, intermittent energy restriction90, endurance 436 
training and nutrition counselling on the Mediterranean diet 81 in individuals at increased risk 437 
of breast cancer are currently underway. These developmental studies point to the feasibility 438 
of initially ‘testing’ complex intervention trials in high-risk populations and should provide both 439 
rational and relevant platforms for planning definitive average-risk population level randomised 440 
controlled trials.  441 
 442 
Conclusions  443 
The need for much greater investment in research into cancer prevention is beyond question, 444 
and yet the current spend is only around 3% of the UK cancer research budget91. Worldwide, 445 
excess weight is associated with the development of at least 480,000 new cancer cases each 446 
year7. The bulk of current observational evidence on weight loss and obesity-related cancers 447 






suggests that decreasing body weight, reducing EBF and maintaining losses, by even 448 
relatively modest amounts, can impact on future cancer risk. It is important to note that most 449 
obese people who lose weight will remain in the obese category but will have reduced cancer 450 
risk by even modest weight loss per se, which should therefore increase motivation 451 
for participating in interventions. However, clear gaps remain in our understanding of how 452 
changes in body fat or increased levels of physical activity are mechanistically linked to a 453 
decreased incidence of cancer. In addition, understanding the impact of different measures of 454 
EBF  (e.g. body mass index, central obesity as assessed by waist circumference, bioelectrical 455 
impedance, DXA, etc.) adds to the complexity of identifying possible solutions11,12,92. These 456 
gaps need to be urgently addressed to expedite the development and implementation of future 457 
cancer control strategies.  458 
Well-designed trials, providing robust evidence of impact, are crucial for efforts to garner 459 
funding for weight management programmes aimed at reducing cancer risk. To date, trials of 460 
weight management and cancer prevention have almost exclusively been confined to 461 
feasibility work. The time has come for an international commitment to decreasing cancer 462 
burden and this commitment includes the development of large-scale intervention trials of 463 
weight management for primary prevention of obesity-related cancer — a point also raised in 464 
the paper on critical research gaps and recommendations in colorectal cancer93. This need is 465 
urgent and the time to act is now!   466 
 467 
Additional Information 468 
Expected effects of lowering BMI on cancer risk –how Mendelian Randomisation can guide 469 
research [Figure 1] 470 
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Figure 1: Current estimates from genetically informed Mendelian randomisation (MR) studies 811 
can be used to set expectations for results of future randomised controlled trials. A recent 812 
meta-analysed MR estimate of BMI for colorectal cancer (from Jarvis et al. 2016. Br J 813 
Cancer) suggests that a 5 kg/m2 lower BMI would reduce risk of developing colorectal 814 






cancer by approximately 20%. This MR estimate reflects lifetime exposure to this relatively 815 
lower BMI, and so the magnitude of reduced colorectal cancer risk in response to short-term 816 
BMI reduction is expected to differ. 817 
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